ROBIN OligoMET Center Monthly Research Update: January 2023

Jefferson.

JANUARY AT A GLANCE TOTALS	
Publications	6
Grants and contracts	
New awards	1
Submitted	3
Oral Presentations	2
Abstracts	0
Clinical trials	
TERPS	1
Awards/Honors	2

eill Cornell

edicine

Please submit all monthly updates to Jadyn Stewart at jadynstewart@som.umaryl and.edu by second Wednesday of each month.

Publications

UNIVERSITY & MARYLAND RADIATION ONCOLOGY

- Hahn NM, O'Donnell MA, Efstathiou JA, Zahurak M, Rosner GL, Smith J, Kates MR, Bivalacqua TJ, Tran PT, Song DY, Baras AS, Matoso A, Choi W, Smith KN, Pardoll DM, Marchionni L, McGuire B, Grace Phelan M, Johnson BA 3rd, O'Neal T, McConkey DJ, Rose TL, Bjurlin M, Lim EA, Drake CG, McKiernan JM, Deutsch I, Anderson CB, Lamm DL, Geynisman DM, Plimack ER, Hallman MA, Horwitz EM, Al-Saleem E, Chen DYT, Greenberg RE, Kutikov A, Guo G, Masterson TA, Adra N, Kaimakliotis HZ. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. Eur Urol. 2023 Jan 28:S0302-2838(23)00025-8. doi: 10.1016/j.eururo.2023.01.017. Epub ahead of print. PMID: 36717286.
- Mell LK, Pugh SL, Jones CU, Nelson TJ, Zakeri K, Rose BS, Zeitzer KL, Gore EM, Bahary JP, Souhami L, Michalski JM, Hartford AC, Mishra MV, Roach M 3rd, Parliament MB, Choi KN, Pisansky TM, Husain SM, Malone SC, Horwitz EM, Feng F. Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial. Eur Urol. 2023 Jan 27:S0302-2838(23)00056-8. doi: 10.1016/j.eururo.2023.01.020. Epub ahead of print. PMID: 36710205.
- Parsons D, Joo M, Iqbal Z, Godley A, Kim N, Spangler A, Albuquerque K, Sawant A, Zhao B, Gu X, Rahimi A. Stability and reproducibility comparisons between deep inspiration breath-hold techniques for left-sided breast cancer patients: A prospective study. J Appl Clin Med Phys. 2023 Jan 23:e13906. doi: 10.1002/acm2.13906. Epub ahead of print. PMID: 36691339.
- 4. Savla B, Hamza MA, Yacubovich D, Cobbs S, Petrovska L, Scilla KA, Burrows W, Mehra R, Miller RC, Rolfo C, Bentzen SM, Mohindra P, Vyfhuis MAL. The impact of Body Mass Index (BMI) and residence in Food Priority Areas (FPAs) on patterns-of-care and cancer outcomes in patients with stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2023 Jan 28:S0360-3016(23)00080-9. doi: 10.1016/j.ijrobp.2023.01.032. Epub ahead of print. PMID: 36720317.
- Sutera P, Deek MP, Van der Eecken K, Shetty AC, Chang JH, Hodges T, Song Y, Verbeke S, Van Dorpe J, Fonteyne V, De Laere B, Mishra M, Rana Z, Molitoris J, Ferris M, Ross A, Schaeffer E, Roberts N, Song DY, DeWeese T, Pienta KJ, Antonarakis ES, Ost P, Tran PT. WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer. Int J Radiat Oncol Biol Phys. 2023 Jan 25:S0360-3016(22)03628-8. doi: 10.1016/j.ijrobp.2022.12.006. Epub ahead of print. PMID: 36708787.
- Ward MC, Fasola CE, White RL Jr, Bentzen SM, Khan AJ, Vicini F, Shah C. In Regard to Vaidya et al. Int J Radiat Oncol Biol Phys. 2023 Jan 1;115(1):255-256. doi: 10.1016/j.ijrobp.2022.10.003. PMID: 36526391.

ROBIN OligoMET Center Monthly Research Update: January 2023

Grants and Contracts

Funded:

• Erika Davies, PhD, PI, from Xequel Bio, Master Service Research Agreement for "Assessing the efficacy of Granexin gel treatment following cutaneous radiation injury in the Yorkshire pig". (2/2023–2/2028). Task order 1: "Pre-study: Begin hiring process for key personnel to perform on anticipated studies" (1/2023-6/2023) (\$384,145).

Submitted:

- Erika Davies, PhD, PI, to PureTech LYT 100, Inc., for "30-day survival efficacy study to determine the effect of LYT-100 following post-irradiation, oral administration on 30-day mortality in the C57BL/6J model of acute radiation injury in the presence or absence of Neulasta treatment" (dates TBD) (\$301,641).
- Erika Davies, PhD, PI, to PureTech LYT 100, Inc., "30-day hematology parameter efficacy study to determine the effect of LYT-100 following post-irradiation, oral administration on recovery from neutropenia, thrombocytopenia and anemia in the C57BL/6J model of acute radiation injury in the presence or absence of Neulasta treatment" (dates TBD). (\$637,241).
- Lei Ren, PhD, Multi-PI (contact PI: Gaykalova, Daria), NIH R01, for "Study of Biological and Radiographic Biomarkers and Association with Ancestry and Survival Disparities in Oral Cavity Squamous Cell Carcinoma Using AI Approaches", (09/2023-08/2028), (\$3,868,431)

Oral Presentations

- Mark M., University of Maryland Baltimore, School of Medicine, Radiation Oncology Symposium Best of 2022 (January 12 Baltimore, MD). "Central Nervous System Best of 2022"
- Zaker R., University of Maryland Baltimore, School of Medicine, Radiation Oncology Symposium Best of 2022 (January 12 Baltimore, MD). "Thoracic Best of 2022"

Abstracts

None Reported

Clinical Trial Enrollment

• 1 patient was enrolled (4/122 total) on the TERPS trial.

Awards/Honors

- Lei R. appointed at Medical Physics Journal as Deputy Editor from January 2023.
- **Phuoc T.** appointed at UM Greenebaum Comprehensive Cancer Center (GCCC) as Director Search Committee.